Novo Shares Plunge 6% Despite CagriSema Beating Lilly In Diabetes Trial

The record

Written from the 1 report below. Nothing here is unsourced.

Novo Nordisk shares dropped 6% after a diabetes trial.
The company's experimental drug CagriSema outperformed a rival treatment from Eli Lilly.
CagriSema is a weekly injectable medication.
It combines the compound cagrilintide with the active ingredient found in Wegovy.

1 report

English national1

All filed from India

Named Denmark · United States · Eli Lilly · CagriSema · Novo Nordisk · Wegovy

The 1 report is listed beside the record.

Answers cite the reports above, or say they can't.